Treatment of the adult Guillain-Barre syndrome: Indications for plasma exchange

Transfusion Science

Volumn 20, Issue 1, 1999, Pages 53-61

  Raphael, J C ^a   Chevret, S ^b   Auriant, I ^a   Sharshar, T ^a   Bouget, J ^c   Bolgert, F ^d  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Clinical trial; Guillain Barre syndrome; Intravenous immune globulin; Plasma exchange

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; STEROID THERAPY; TREATMENT INDICATION;

GUILLAIN-BARRE SYNDROME; HUMANS; PLASMA EXCHANGE; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0032927451     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00092-7     Document Type: Conference Paper

References (39)

1. Ropper AH, Wijdicks EFM. Truax BT Contemporary Neurology Series Philadelphia: F.A. Davis company, 1991.
2. Raphael JC, Masson C, Morice V, Brunei D, Gajdos Ph, Barois A, et al. Le syndrome de Landry-Guillain-Barré. Etude des facteurs pronostiques dans 223 cas. Rev Neurol. 1986;142:613-24.
3. French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992;32:94-7.
4. French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Annals of Neurology 1997;41:298-306.
5. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillian-Barré syndrome. Lancet 1997;349:225-30.
6. Van Der Meché FGA, Schmitz PIM, the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globin and plasma exchange in Guillain-Barré syndrome. New Engl J Medicine 1992;326: 1123-9.
7. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109:1115-26.
8. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillian-Barré syndrome: Evidence of two different mechanisms? J Neurol Sci 1993;116:185-92.
9. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. New England Journal of Medicine 1995;333:1374-9.
10. McKhann GM, Cornblath DR, Ho TW, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-7.
11. McKhann GM, Cornblath DR, Griffin JW. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Annals of Neurology 1993;33:333-42.
12. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
13. Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997;48:695-700.
14. French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann neurol 1987;22:753-61.
15. Hartung HP, Schafer B, Heininger K, Stoll G, Toyka KV. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Brain 1988;111:1039-59.
16. Watts PM, Taylor WA, Hughes RAC. High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat. Exp neurol 1989;103:101-4.
17. Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976;26:205-12.
18. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-3.
19. Guillain-Barré Syndrome Steroidal Trial Group. Double-blind of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-90.
20. Harrison BM, Hansen LA, Pollard JD, McLeod JG. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann Neurol 1984;15:163-70.
21. Metral S, Raphael JC, Hort-Legrand Cl, Elkharrat D. Activité démyélinisante sérique et syndrome de Guillain-Barré: effect favorable des échanges plasmatiques. Rev Neurol 1989;145:312-9.
22. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-104.
23. Greenwood RJ, Newsom-Davis J, Hughes RAC, Aslan S, Bowden AN, Chadwick DW, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-9.
24. Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Siden A, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2:1296-8.
25. Bouget J, Chevret S, Chastang CI, Raphael JC, the French Cooperative Group. Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, double-blind, randomized, multicenter study. Critical Care Medicine 1993;21:651-8.
26. Farkkila M, Kinnunen E, Haapanen E, Iivanainem M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 1987;37:837-84.
27. Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, et al. Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology 1985;35:1551-5.
28. Imbach P, Barabdum S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1128-31.
29. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE, Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984;2:765-8.
30. Vermeulen M, Van der Méché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317-26.
31. Van der Méché FGA, Vermeulen M, Busch HFM. Chronic inflammatory demyelinating polyneuropathy: Conduction failure before and during immunoglobulin or plasma therapy. Brain 1989;112:1563-71.
32. Kleyweg RP, Van der Méché FGA, Meulstee J Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology. 1988;38:1639-41.
33. Raphael JC, Chevret S, Chastang CI, Gajdos Ph. Intravenous immune globuline versus plasma exchange in Guillain-Barré syndrome (letter). New Engl J Medicine 1992;327:816.
34. Van der Méché FGA, Schmitz PIM, Kleyweg RP. Intravenous immune globulin versus plasma exchange in Guillain-Barré syndrome (letter). New England Journal of Medicine 1992;327:816.
35. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology 1993;43.
36. Irani DN, Cornblath DR, Chaudry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-5.
37. Raphael JC. Prise en charge d'un syndrome de Guillain-Barré. In: Gajdos Ph, Loh L, editors. Réanimation et Neurologie. Paris: Arnette Blackwell 1995:271-87.
38. Thorton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:260-8.
39. Minvielle E, Viens-Bitker C, Rochant H, et al. La maîtrise de la diffusion d'une innovation en santé: le cas des immunoglobulines intraveineuses polyvalentes à l'Assistance Publique-Hôpitaux de Paris. Ann Med Interne 1995;146:19-24.